Description
Benefits
- Strongly lowers ApoB, a key driver of cardiovascular risk
- Potent LDL reduction at relatively low doses
- Long half-life allows for flexible dosing strategies
- Lower likelihood of muscle- and cognition-related side effects compared to older statins
- Supports plaque stabilization and vascular health
- Commonly used in longevity-focused cardiovascular risk reduction
Background and History
- Statins were developed to reduce cholesterol synthesis via HMG-CoA reductase inhibition
- ApoB emerged as a superior predictor of cardiovascular risk compared to LDL alone
- Rosuvastatin was developed as a high-potency, next-generation statin
- It demonstrated strong LDL and ApoB reduction with lower systemic exposure
- Research showed additional benefits on inflammation and plaque stabilization
- These features led to widespread adoption in preventive cardiology and longevity medicine
